We are live on ! Find out more
BBIO icon

BridgeBio Pharma
BBIO

75 hedge funds and large institutions have $2.22B invested in BridgeBio Pharma in 2019 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 18

23% more funds holding

Funds holding: 61 → 75 (+14)

20% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 15

1.58% more ownership

Funds ownership: 86.89% → 88.47% (+1.6%)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

18% less capital invested

Capital invested by funds: $2.7B → $2.22B (-$478M)

Holders
75
Holders Change
+14
Holders Change %
+22.95%
% of All Funds
1.64%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.11%
New
33
Increased
18
Reduced
15
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
+$56.3M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$41.7M
3
BlackRock
BlackRock
New York
+$39.3M
4
TCM
TimesSquare Capital Management
New York
+$10.7M
5
State Street
State Street
Massachusetts
+$9.73M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$10.5M
2
Millennium Management
Millennium Management
New York
-$9.48M
3
JP Morgan Chase
JP Morgan Chase
New York
-$9.09M
4
Fidelity International
Fidelity International
Bermuda
-$7.81M
5
SM
SCGE Management
California
-$4.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity International
76
Fidelity International
Bermuda
– -$7.81M -289,448 Closed
Alyeska Investment Group
77
Alyeska Investment Group
Illinois
– -$1.76M -65,154 Closed
MIM
78
Monashee Investment Management
Massachusetts
– -$1.35M -50,000 Closed
MS
79
Maven Securities
Jersey
– -$1.02M -39,850 Closed
LCM
80
Landscape Capital Management
New Jersey
– -$1.04M -38,679 Closed
ACH
81
ArrowMark Colorado Holdings
Colorado
– -$809K -30,000 Closed
CS
82
Credit Suisse
Switzerland
– -$701K -26,000 Closed
DKCM
83
Davidson Kempner Capital Management
New York
– -$675K -25,000 Closed
Citadel Advisors
84
Citadel Advisors
Florida
– -$601K -22,281 Closed
DIM
85
DC Investments Management
Virginia
– -$587K -21,779 Closed
AGU
86
Alpine Group USVI
U.S. Virgin Islands
– -$539K -20,000 Closed
SG Americas Securities
87
SG Americas Securities
New York
– -$476K -17,647 Closed
Point72 Asset Management
88
Point72 Asset Management
Connecticut
– -$356K -13,200 Closed
PHK
89
Point72 Hong Kong
Hong Kong
– -$255K -9,437 Closed
Federated Hermes
90
Federated Hermes
Pennsylvania
– -$135K -5,000 Closed
AAMU
91
Amundi Asset Management US
Massachusetts
– -$13K -500 Closed
CCA
92
Catalyst Capital Advisors
New York
– -$8K -285 Closed
FIA
93
FNY Investment Advisers
New York
– -$6K -256 Closed
1 2 3
4

BBIO Hedge Fund Activity: Q3 2019 in Review

75 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q3 2019, worth a combined $2.22B — down 18% from $2.7B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new BBIO positions and 18 closed out — a net gain of 15 holders — while 18 added to existing stakes and 15 trimmed.

The largest buyer was HHLR Advisors, adding an estimated $56.3M. The largest seller was Fidelity Investments, cutting an estimated $10.5M.

  • 75 institutional investors held BridgeBio Pharma (BBIO) as of Q3 2019, up from 61 in Q2 2019.
  • Funds reported $2.22B of BridgeBio Pharma stock for Q3 2019, down 18% quarter-over-quarter.
  • 33 funds opened new BridgeBio Pharma positions in Q3 2019 and 18 closed out, a net change of +15 holders.
  • The largest BridgeBio Pharma buyer in Q3 2019 was HHLR Advisors, an estimated $56.3M added.
  • The largest BridgeBio Pharma seller in Q3 2019 was Fidelity Investments, an estimated $10.5M sold.

Based on aggregated 13F filings for Q3 2019.